A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery

To evaluate safety and efficacy of MD-15 intraocular lens implanted into the aphakic eyes

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cataract Eye Diseases Lens Diseases

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Tokyo, Japan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients who intend to undergo phacoemulsification cataract extraction

Exclusion criteria

Patients who undergo secondary implantation
Patients with vision loss induced by causes other than cataract
Patients who the principal investigator/subinvestigator considers ineligible for enrollment

Treatment and study plan

MD-15 Intraocular Lens

Device

Primary outcomes

Corrected visual acuity

Time frame: Week 52

Sponsors and collaborators

Lead sponsor

Santen Pharmaceutical Co., Ltd.

Industry

Registry information

Official study title

Open Label, Phase/3 Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery

Important dates

Study start: 2016
Primary completion: 2017
Study completion: 2017
First posted: Sep 2, 2016
Registry last updated: Feb 27, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed